$10.27
0.58%
Downside
Day's Volatility :1.59%
Upside
1.01%
14.8%
Downside
52 Weeks Volatility :48.59%
Upside
39.66%
Period | Abivax S.a. | Index (Russel 2000) |
---|---|---|
3 Months | -7.06% | 0.0% |
6 Months | -29.37% | 0.0% |
1 Year | 1.68% | 0.0% |
3 Years | 23.73% | -26.4% |
Market Capitalization | 673.7M |
Book Value | $2.01 |
Earnings Per Share (EPS) | -3.71 |
Wall Street Target Price | 36.09 |
Profit Margin | 0.0% |
Operating Margin TTM | -1178.84% |
Return On Assets TTM | -46.69% |
Return On Equity TTM | -171.46% |
Revenue TTM | 9.0M |
Revenue Per Share TTM | 0.16 |
Quarterly Revenue Growth YOY | 201.9% |
Gross Profit TTM | 0.0 |
EBITDA | -169.9M |
Diluted Eps TTM | -3.71 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | -3.05 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 251.41%
Sell
Neutral
Buy
Abivax S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Abivax S.a. | -0.19% | -29.37% | 1.68% | 23.73% | 23.73% |
Regeneron Pharmaceuticals, Inc. | -16.85% | -11.85% | 3.27% | 29.37% | 171.22% |
Biontech Se | -6.94% | 20.23% | 16.39% | -62.26% | 487.66% |
Alnylam Pharmaceuticals, Inc. | 1.63% | 79.81% | 63.67% | 58.45% | 198.57% |
Vertex Pharmaceuticals Incorporated | 3.87% | 17.46% | 25.23% | 149.18% | 136.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Abivax S.a. | NA | NA | NA | 0.0 | -1.71 | -0.47 | NA | 2.01 |
Regeneron Pharmaceuticals, Inc. | 20.75 | 20.75 | 1.18 | 44.77 | 0.17 | 0.08 | NA | 242.47 |
Biontech Se | 160.8 | NA | 0.04 | -2.76 | -0.03 | -0.02 | NA | 80.22 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.39 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.21 | 0.16 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Abivax S.a. | Buy | $673.7M | 23.73% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $101.7B | 171.22% | 20.75 | 32.04% |
Biontech Se | Buy | $27.1B | 487.66% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 198.57% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $122.9B | 136.25% | 32.84 | -4.74% |
Insights on Abivax S.a.
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.7% return, outperforming this stock by 62.0%
Organization | Abivax S.a. |
Employees | 62 |
CEO | Mr. Marc M. P. de Garidel M.B.A. |
Industry | Miscellaneous |
Victoryshares International
$10.27
-0.48%
Clearbridge Focus Value Esg Etf
$10.27
-0.48%
Cabana Target Drawdwn 10 Etf
$10.27
-0.48%
Spdr Nyse Technology Etf
$10.27
-0.48%
Cp High Yield Trend Etf
$10.27
-0.48%
Gain Therapeutics Inc
$10.27
-0.48%
Spdr S&p Emerging Markets Ex-china Etf
$10.27
-0.48%
Proshares Bitcoin Strategy Etf
$10.27
-0.48%
Xtrackers Msci Kokusai Eqty
$10.27
-0.48%